Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
RA Pharmaceuticals was a clinical-stage biopharmaceutical company committed to developing novel therapies for patients suffering from rare complement-mediated diseases. Its lead product candidate, Zilucoplan, a self-administered peptide inhibitor of complement component 5 (C5), was being developed for generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), and other tissue-based complement-mediated disorders. Founded in 2008 and headquartered in Cambridge, Massachusetts, RA Pharmaceuticals made significant advancements in the field before being acquired by UCB in April 2020 for approximately $2.1 billion (net of cash). This acquisition was aimed at bolstering UCB's portfolio in neurology and immunology, particularly in treating rare diseases.
Served as the central hub for corporate operations, research and development (R&D) laboratories, clinical trial management, and administrative functions supporting the company's drug development pipeline.
Strategically located in Kendall Square, a leading global biotech innovation hub, providing proximity to world-class research institutions, talent, and potential collaborators. The facility likely included modern laboratory and office spaces tailored for biopharmaceutical research.
Characterized by a fast-paced, science-driven, and collaborative environment typical of clinical-stage biotechnology companies. There was likely a strong emphasis on innovation, scientific rigor, and a patient-focused mission.
The Cambridge headquarters was pivotal for RA Pharmaceuticals' progress, enabling the discovery and development of its complement C5 inhibitor pipeline, including Zilucoplan. Its location facilitated access to essential resources and talent in the competitive biotech landscape.
Prior to its acquisition by UCB, RA Pharmaceuticals's global presence was primarily driven by its international clinical trial activities for Zilucoplan, which involved study sites across North America, Europe, and other key regions. While direct international office infrastructure was limited, the company collaborated with global clinical research organizations (CROs) and academic institutions to conduct its research and development programs worldwide. Its strategic focus was on advancing its pipeline through these global collaborations rather than establishing a widespread physical office network.
800 Technology Square
Cambridge
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, RA Pharmaceuticals' leadership includes:
RA Pharmaceuticals has been backed by several prominent investors over the years, including:
In the 12-18 months preceding its acquisition announcement in October 2019, RA Pharmaceuticals made strategic additions to its executive team, notably appointing a new Chief Financial Officer and a Chief Commercial Officer. This period also saw the departure of its previous CFO. Following the acquisition by UCB in April 2020, the RA Pharmaceuticals executive team was integrated into UCB or transitioned out.
Discover the tools RA Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by UCB, RA Pharmaceuticals likely utilized standard corporate email address formats. While specific internal policies are not public, common patterns in the biopharmaceutical industry include combinations of first name, last name, and initials. Post-acquisition, official communications would transition to UCB's email systems.
A common email format at RA Pharmaceuticals was likely `[first_initial][last]@rapharma.com`.
Format
jdoe@rapharma.com
Example
75%
Success rate
UCB Press Release • October 10, 2019
UCB and RA Pharmaceuticals announced a definitive agreement under which UCB would acquire RA Pharma for $48 per share in cash, equating to an approximate enterprise value of $2.1 billion (net of cash). The acquisition aimed to enhance UCB's leadership in treating myasthenia gravis and other rare diseases by adding RA Pharma's lead candidate, Zilucoplan, to its portfolio....more
Business Wire (RA Pharma Press Release) • December 4, 2018
RA Pharmaceuticals reported positive topline results from its Phase 2 clinical trial evaluating Zilucoplan in patients with generalized myasthenia gravis (gMG). The trial successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in disease severity scores compared to placebo....more
UCB Press Release • April 2, 2020
UCB announced the successful completion of its acquisition of Ra Pharmaceuticals, Inc. This transaction further strengthened UCB's pipeline with Zilucoplan, a promising therapy for severe chronic rare diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including RA Pharmaceuticals, are just a search away.